Lawyers involved in the federal litigation over gadolinium-based contrast agents, which have been linked to the development of a debilitating condition known as Nephrogenic Systemic Fibrosis, are scheduled to meet with the Court today to discuss the process for selecting the first NSF lawsuits for trial and the status of the plaintiffs’ ability to identify which of the five different gadolinium contrast agents were used in each case. Continued
All Posts Tagged With: "Gadolinium"
Gadolinium Litigation Involves 391 Lawsuits in State and Federal Court
According to documents filed in federal court, the makers of gadolinium-based contrast agents currently face 391 lawsuits filed by individuals who allege that they developed a rare condition known as NSF, or nephrogenic systemic fibrosis, after an enhanced MRI. Continued
FDA Reviewing New MRI Contrast Agent as Alternative to Gadolinium
The FDA has granted a Fast Track Designation to a new type of MRI contrast agent, ferumoxytol, which could be a safer alternative to gadolinium-based contrast agents for individuals with chronic kidney problems. Continued
MRI Contrast Lawsuits Filed in St. Claire County Illinois State Court
At least two gadolinium lawsuits were filed earlier this month in Illinois State Court on behalf of individuals diagnosed with a severe and disabling skin condition after receiving an MRI contrast agent. Continued
Nephrogenic Systemic Fibrosis Lawsuit
Gadolinium based contrast agents used during MRI and MRA tests could cause nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy (NFD) for individuals with moderate to severe kidney problems. The devastating condition could have been avoided by hundreds of people throughout the United States if the manufacturers of these contrast agents had warned about the potential MRI problems. Continued
